Abstract
Vaccine solutions rarely reach the public until after an outbreak abates; an Ebola vaccine was approved 5 years after peak outbreak and SARS, MERS, and Zika vaccines are still in clinical development. Despite massive leaps forward in rapid science, other regulatory bottlenecks are hamstringing the global effort for pandemic vaccines.
| Original language | English |
|---|---|
| Pages (from-to) | 943-947 |
| Number of pages | 5 |
| Journal | Trends in Biotechnology |
| Volume | 38 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sept 2020 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver